Table 5.
CYP2C19 metabolizer status distribution in controls and cases with MDD and BPD
| Control(n = 464) | MDD(n = 439) | BPD(n = 600) | ||||
|---|---|---|---|---|---|---|
| NM | 248 (53.45%) | 187 (42.60%) | 233 (38.83%) | |||
| IM | 160 (34.48%) | 195 (44.42%) | 283 (47.17%) | |||
| PM | 56 (12.07%) | 57 (12.98%) | 84 (14.00%) | |||
| IM&PM | 216 (46.55%) | 252 (57.40%) | 367 (61.17%) | |||
| MDD | BPD | |||||
| χ2 | P | OR (CI 95%) | χ2 | P | OR (95% CI) | |
| NM vs. IM vs. PM | 11.330 | 0.003 | –– | 23.215 | < 0.001 | –– |
| IM&PM vs. NM | 10.639 | 0.001 | 1.547(1.190,2.012) | 22.563 | < 0.001 | 1.808(1.415,2.311) |
NM Normal metabolizer, IM Intermediate metabolizer, PM Poor metabolizer, IM&PM Intermediate metabolizers plus poor metabolizers